General Collaboration Sample Clauses

General Collaboration. 3.1 The Governments of Canada and Québec will work in concert on all votes, resolutions, negotiations and proposed international instruments at UNESCO. In the absence of consensus between the Governments of Canada and Québec, and at the request of the latter, the Government of Canada will provide a note explaining its decision to the Government of Québec. Québec alone will decide if it proceeds with implementation in areas of its responsibility.
Sample 1
AutoNDA by SimpleDocs
General Collaboration. In a constant effort to improve the quality offered to our beneficiaries, XXX and the JSIS will meet on a regular basis. The purpose of these meetings will be to assess and verify the proper performance of the services provided and the practical follow-up of optional or complementary tests. Clinical responsibility This agreement does not in any way alter the contractual relationship between XXX and the beneficiary of the JSIS who contacts XXX in the framework of the screening programme. XXX will provide, on request, the certificate of insurance against civil liability, covering the risks of the profession and will be up to date in the payment of its premiums. The JSIS cannot be held liable for any problems/damage that the beneficiary may suffer on the occasion and/or following the carrying out of screening programmes by XXX. The medical report must be sent to the beneficiary and, where appropriate, to his/her own doctor upon the beneficiary’s written consent. Processing of personal data XXX and the JSIS are bound by Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 and by Regulation (EU) 2018/1725 of the European Parliament and of the Council of 23 October 2018 as regards their respective fields of application. The Parties agree that each party is an independent (and not joint) controller of the personal data of the beneficiaries and shall be solely responsible for its compliance with its respective Regulation. The beneficiary of the JSIS is free to decide where to carry out the tests under the corresponding screening programme. If he/she chooses XXX as an approved centre with whom the JSIS has concluded an agreement to simplify the handling of the tests, he/she will give the letter of invitation to XXX when he/she presents himself/herself at the appointment he/she had made himself/herself with XXX. Apart from the direct transmission of invoices by XXX to the JSIS, no personal or medical information is exchanged between XXX and the JSIS. The JSIS informs the beneficiaries that, by giving the letter of invitation to the XXX, they agree that the invoice for the tests carried out should be sent directly to the JSIS. The JSIS informs the beneficiaries that, by accepting the programme, they accept that the information contained in the invitation letter is used by XXX for the purpose of carrying out the screening programme.
Sample 1
General Collaboration. 3. Professional Development
Sample 1
General Collaboration. Xxxxxx will use reasonable endeavours to reasonably collaborate with Harman to secure additional distribution with Approved OEMs in the OEM Market, including undertaking reasonable marketing and brand-building activities requested by Harman and subject to reimbursement from Harman of the costs (pre-approved by Harman) of such requested activities. For the purpose of promoting the Xxxxxx Products, upon Xxxxxx’x request and free-of-charge to Harman, Xxxxxx agrees to provide Harman with access to and use of existing Xxxxxx marketing assets (such as marketing videos, brochures, etc.) to the extent that these are relevant to the Xxxxxx Products only and to make Xxxxxx technicians and other appropriate employees available to Harman for brand immersion events, training events or the like, in each case as agreed between the Parties in writing. Xxxxxx agrees that Harman and/or the Approved OEMs may purchase Xxxxxx Consumer Products, for marketing or promotion of the Xxxxxx Products, from time to time at such discounted prices as are consistent with pricing offered by Xxxxxx to Harman prior to the Amendment Effective Date. The Parties agree to negotiate in good faith regarding any reasonable amendments to Section IV (Royalties) if such amendments are necessary to secure such additional distribution with Approved OEMs.
Sample 1
General Collaboration. The Parties enter into this Agreement for the purpose of granting secondary naming rights for the Downtown Doral Park and naming rights for the Doral Cultural Arts Center, as more particularly set forth in Exhibit “A”.
Sample 1

Related to General Collaboration

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development of Products (a) During the term of this Agreement, ViewRay may from time to time seek services from PEKO with respect to the development of certain Products that can be incorporated into the ViewRay Renaissance™ MRI-guided radiation therapy system. For each Program to be undertaken by PEKO pursuant to this Agreement, the parties will prepare a “Work Statement” and agree to said “Work Statement” in substantially the form attached as Attachment 1. Each Work Statement will describe: (i) the (i) services that PEKO will be responsible for providing to ViewRay and the deliverables that PEKO will be responsible for delivering to ViewRay (“Deliverable(s)”), (ii) delivery schedule for the Deliverables, (iii) pricing terms, (iv) work plan for the Program, and (v) ViewRay’s responsibilities in connection with the Program. Each Work Statement will be prepared based upon the requirements and information provided to PEKO by ViewRay. A separate Work Statement will be required for each Program; and each Work Statement will become subject to this Agreement only when mutually agreed and signed by ViewRay and PEKO.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Manufacturing Technology Transfer With respect to each Technology Transfer Product, upon AbbVie’s written request after the Inclusion Date for the Included Target to which such Technology Transfer Product is Directed, Morphic shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party manufacturer) of all Morphic Know-How and Joint Know-How relating to the then-current process for the Manufacture of such Technology Transfer Product (the “Manufacturing Process”) and to implement the Manufacturing Process at facilities designated by AbbVie (such transfer and implementation, as more fully described in this Section 5.3, the “Manufacturing Technology Transfer”). To assist with the Manufacturing Technology Transfer, Morphic will make its personnel reasonably available to AbbVie during normal business hours for up to [***] FTE hours with respect to each Included Target (in each case, free of charge to AbbVie) to transfer and implement the Manufacturing Process under this Section 5.3. Thereafter, if requested by AbbVie, Morphic shall continue to perform such obligations; provided, that AbbVie will reimburse Morphic for its full-time equivalent (FTE) costs (for clarity, in excess of [***] FTE hours) and any reasonable and verifiable out-of-pocket costs incurred in providing such assistance. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED.

  • Research License Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.

Time is Money Join Law Insider Premium to draft better contracts faster.